Skip to main content Help with accessibility Skip to main navigation

Risedronate sodium

Background

Oral bisphosphonates (alendronic acid, ibandronic acid and risedronate sodium) are recommended as options for treating osteoporosis in adults only if:
•the person is eligible for risk assessment as defined in NICE’s guideline on osteoporosis (recommendations 1.1 and 1.2) and
•the 10‑year probability of osteoporotic fragility fracture is at least 1%.
Intravenous bisphosphonates (ibandronic acid and zoledronic acid) are recommended as options for treating osteoporosis in adults only if:
•the person is eligible for risk assessment as defined in NICE’s guideline on osteoporosis (recommendations 1.1 and 1.2) and
•the 10‑year probability of osteoporotic fragility fracture is at least 10% or
•the 10‑year probability of osteoporotic fragility fracture is at least 1% and the person has difficulty taking oral bisphosphonates (alendronic acid, ibandronic acid or risedronate sodium) or these drugs are contraindicated or not tolerated

 

Recommendation

LSCMMG Recommendation:

Green

Reason for decision:

Suitable for initiation in primary care

Supporting documents:

Decisions of Lancashire local decision making groups

Green
Green
Green
Green
Green
Green
Green
Green
What do the colours mean?

Last Updated: 01 - Sep - 2017